Apollo Healthtech, the digital health and pharmacy unit of Apollo Hospitals, is set to list between January and March 2027, according to the Apollo’s chief financial officer.

Apollo Hospitals, based in India, operates a nationwide hospital network.

The company said the demerger aims to unlock value for shareholders, with no changes in promoter involvement.

In Q1, Apollo Hospitals posted a 42% year-on-year profit rise to 433 crore rupee (US$49.4 million) and a 15% revenue growth to 5,842 crore rupee (US$670 million), driven by more patients and expanded diagnostics.

Earnings before interest, taxes, depreciation, and amortisation rose 26% to 852 crore rupee (US$97.2 million).

The company has applied for approval from stock exchanges and will seek clearance from India’s Competition Commission and National Company Law Tribunal.

Apollo Hospitals plans to add over 4,300 beds in the next five years, with an investment of more than 7,600 crore rupee (US$867.4 million).

🔗 Source: The Economic Times

🧠 Food for thought

1️⃣ Healthcare demergers follow a proven playbook for unlocking focused growth

Apollo’s demerger strategy aligns with successful corporate restructuring patterns seen across Indian conglomerates in recent years.

Wipro adopted a similar approach in 2012 when it spun off its Consumer Care & Lighting, Infrastructure Engineering, and Medical Diagnostic businesses into Wipro Enterprises. This allowed its dominant IT business—which contributed 86% of revenue and 94% of operating profit—to operate with sharper focus 1.

The rationale remains consistent: separating high-growth digital assets from traditional operations enables dedicated management teams and targeted capital allocation for each business vertical.

Apollo’s approach of maintaining the same promoter structure while creating operational independence suggests confidence that both entities can achieve premium valuations when managed as focused, pure-play businesses rather than diversified conglomerates.

2️⃣ Apollo’s timing capitalizes on India’s explosive e-pharmacy growth trajectory

The 2027 listing timeline positions Apollo Healthtech to capture value from India’s rapidly expanding digital pharmacy market, which is projected to grow from $3.18 billion in 2024 to $12.71 billion by 2033—a robust 16.65% compound annual growth rate 2.